|Immunicum "takes revenge" with very good data from MERECA according to a newsrelease today :|
Short sellers have contributed to a huge stock pullback the last few weeks, but now the doubts of ilixadencel's potential as an effective immune primer should be very much reduced.
"Immunicum AB (publ) Announces Complete Topline Data Analysis from Phase II MERECA Trial
25 September 2019
Immunicum AB (publ) Announces Complete Topline Data Analysis from Phase II MERECA Trial
--Survival as of July 2019 was 57% (32 out of 56) of patients treated with ilixadencel compared with 43% (13 out of 30) of patients who did not receive ilixadencel; the median Overall Survival final value cannot yet be calculated in either group as the data is not mature enough--
--The Objective Response Rate (ORR), measured in all patients receiving sunitinib was 44% (20 out of 45 patients) in the ilixadencel combination group and 48% (12 out of 25 patients) in the sunitinib monotherapy group, while the number of Complete Responders was 11% (5 out of 45) and 4% (1 out of 25) in the respective groups--
--The median Duration of Response was 7.1 months for the ilixadencel combination group versus 2.9 months in the sunitinib monotherapy group over the 18 months study period—
--The overall safety data was similar in both treatment groups, meaning ilixadencel did not add toxicity, which supports ilixadencel’s favorable safety profile--"